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Abstract
Background: SLC34A2 with highest expressions in lung, small intestine and kidney encoded a type 2b sodium-dependent
phosphate transporter (NaPi-IIb). In lung, SLC34A2 only expressed in the apical membrane of type II alveolar epithelium
cells (ATII cells) and played a pivotal role during the fetal lung development and embryonic development. ATII cells
acting as multifunctional stem cells might transform into NSCLC after undergoing exogenous or endogenous factors.
Increasing evidences showed that the genes performing critical roles during embryogenesis were also expressed
during the development of cancer. In addition, recent research found the expression of SLC34A2 had a significant
difference between the surgical samples of NSCLC and normal tissues, and SLC34A2 was down-regulated in lung
adenocarcinoma cell line A549 and up-regulation expression of SLC34A2 could significantly inhibit cell viability and
invasion of A549 in vitro. These results suggested SLC34A2 might play an important role in the development of NSCLC.
However, the role of SLC34A2 in tumorigenesis and progression of NSCLC remains unknown.
Results: Our study found that SLC34A2 was also significantly down-regulated in 14/15 of examined NSCLC tissues.
Moreover, we found that expressions of SLC34A2 were reduced in six NSCLC cell lines for the first time. Our result also
revealed a dramatic inhibitory effects of SLC34A2 on cell growth, migration and invasion of several NSCLC cell lines.
SLC34A2 also strongly inhibited tumor growth and metastasis ability in A549 subcutaneous tumor model and lung
metastasis model, respectively. Further studies found that the suppressive effects of SLC34A2 on tumorigenesis
and progression might be associated with the down-regulation of related protein in PI3K/Akt and Ras/Raf/MEK
signal pathway.
Conclusions: For the first time, our data indicated that SLC34A2 could exert significantly suppressive effects on
tumorigenesis and progression of NSCLC. SLC34A2 might provide new insights for further understanding the early
pathogenesis of human NSCLC.
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Background
Despite advances in early detection and standard treat-
ment, NSCLC still has a poor 5-year survival and it is
often diagnosed at an advanced stage [1]. Therefore,
there is a great need to understand the pathogenesis of
NSCLC clearly in order to define new biomarkers of
early diagnosis and find new targets for NSCLC therapy.
Human SLC34A2 cDNA was first isolated and cloned
from a human small intestine and lung cDNA library re-
spectively in 1999 [2, 3]. SLC34A2 encodes a type 2b
sodium-dependent phosphate transporter, NaPi-IIb. It is
a multi-pass membrane protein, composed of 690 amino
acids. This protein has been reported to mediate trans-
porting inorganic phosphate into epithelial cells via so-
dium ion co-transport and have a role in the synthesis of
surfactants in lung alveoli [4]. Recent studies pointed
that although SLC34A2 was expressed in various human
tissues, the highest expressions were shown in lung,
small intestine and kidney [3, 5]. In lung, expression of
SLC34A2 was only found in the apical membrane of type
II alveolar epithelium cells (ATII), thus it could be
regarded as a candidate specific marker for ATII cells
[4–6]. SLC34A2 played a significant role in ATII cells
[6]. The anomalous expression of SLC34A2 might result
in functional disorder of ATII cells. Some research
showed that mutations in SLC34A2 caused Pulmonary
Alveolar Microlithiasis (PAM) [7] and anomalous ex-
pression of SLC34A2 was responsible for some other dis-
eases such as hypophosphatemia, infertility and
Testicular Microlithiasis (TM) [7, 8]. Besides, recent re-
search reported that SLC34A2 was down-regulated in
breast cancer, but overexpression of SLC34A2 was de-
tected in ovarian cancer and papillary thyroid cancer [8].
These studies indicated that SLC34A2 was related to
tumorigenesis and progression. However, the researches
about the function of SLC34A2 in tumorigenesis and de-
velopment, especially the relationship between SLC34A2
and lung cancer, have not been reported until now.
Recently, Eugene P. Kopantzev reported the expression
of SLC34A2 in human lung development. The expres-
sion of SLC34A2 was augmented in human fetal lung de-
velopment, and reached highest level at the canalicular
stage of lung development which remained unchanged
during further development [9]. Meanwhile, Mitsuyoshi
Hashimoto observed that SLC34A2 was first faintly de-
tected on gestational day 16.5, but rapidly augmented
after gestational day 18.5 in the developing rat lung, fi-
nally kept the constant level even after postnatal day
until adult [5]. Moreover, SLC34A2 was essential for em-
bryonic development. Homozygous SLC34A2 deficient
mice died in uterus soon after implantation. NaPi-IIb
was detected at the point where embryonic and maternal
circulations were in closest contact [10]. These results
suggested that SLC34A2 locating in AT-II cells played a
pivotal role during the fetal lung development and em-
bryonic development.
Increasing evidents showed that genes performing crit-
ical roles during embryogenesis were also expressed dur-
ing the development of cancer, especially genes which
were associated with deprogramming and maintaining the
undifferentiated stem cell state [11, 12]. For example,
Ovca1 is a tumor suppressor that can modify p53-induced
tumorigenesis and participate in the tumorigenesis. More-
over, Ovca1–2 or Ovca1 homozygous mutants died soon
after birth, which suggested that Ovca1 was required for
embryonic development and postnatal viability [13].
Therefore, we supposed that SLC34A2, which played a
pivotal role in embryonic development and the fetal lung
development, might participate in the tumorigenesis and
progression of lung cancer.
Otherwise, recent researches showed that ATII cells
could serve as the stem cells of the alveolar epithelium
[14]. Moreover, Gurmukh [15] showed that lung carcin-
omas exhibited the feature of ATII cells, like the pres-
ence of lamellar bodies in the cytoplasm and tubular
electron-microscopic nuclear inclusions. Meanwhile,
they identified the existent of ATII cells in those lung
carcinomas by immunoperoxidase staining with surfac-
tant specific apoprotein. In addition, Kitinya [16] and
Gazdar [17] found that large cell carcinoma and adeno-
carcinoma histogenetically were related to ATII cells by
using monospecific IgG against pulmonary surfactant
apoprotein. These evidences demonstrated that ATII
cells might be the cell of origin of several types of lung
cancer including large cell carcinoma and adenocarcin-
oma [16, 17]. Because in lung, the expression of
SLC34A2 was only found in ATII cells and ATII cells
might be the origin of several types of lung cancer.
These facts further suggested that SLC34A2 might play
an important role in tumorigenesis of NSCLC.
Particularly in 2008, Eugene P. Kopantzev demonstrated
that the expression of SLC34A2 in human normal lung tis-
sue was ten times higher than that in surgical samples of
NSCLC [9]. Foremost, our recent research found that ex-
pression of SLC34A2 was down-regulated in lung adeno-
carcinoma cell line A549 and elevated expression of
SLC34A2 could significantly inhibit cell viability and inva-
sion of A549 in vitro [18]. However, until now, there are
not any reports about the effects of SLC34A2 on tumori-
genesis and development of NSCLC.
To explore the effects of SLC34A2 on tumorigenesis
and development of NSCLC, the expressions of SLC34A2
in 15 NSCLC tissues and 6 NSCLC cell lines were exam-
ined in this study firstly. Secondly, effects of SLC34A2
on NSCLC cell proliferation, apoptosis, migration and in-
vasion were investigated in vitro. Thirdly, effects of
SLC34A2 on NSCLC growth and metastasis ability were fur-
ther identified with A549 subcutaneous xenotransplanted
Wang et al. Journal of Biomedical Science  (2015) 22:52 Page 2 of 12
tumor model and lung metastasis model. Finally, potential
mechanisms of SLC34A2 were further evaluated. For the
first time, our study focused on the effects of SLC34A2 on
tumorigenesis and development of NSCLC. It will be helpful
for deeply understanding the tumorigenesis and pathogen-
esis of NSCLC.
Methods
Cell lines and animals
The NSCLC cell lines A549, H1299, H460 and Human
bronchial epithelial cell HBE were purchased from American
Type Culture Collection (ATCC, Manassas, VA, USA). The
NSCLC cell lines H358, 95D and SK-MES-1 were pur-
chased from Cell Bank of the Chinese Academy of Sciences
(Shanghai, China). The cell lines A549, H1299, H460 and
H358 were maintained in RPMI-1640 (Gibco Laboratories,
Grand Islands, NY, USA) containing 10 % heat-inactivated
fetal bovine serum (FBS) (Gibco, Gaithersburg, USA). The
cell lines HBE, 95D and SK-MES-1 was maintained in
DMEM (Gibco Laboratories, Grand Islands, NY, USA)
supplemented with 10 % heat-inactivated FBS (Gibco,
Gaithersburg, USA). All cells were cultured at 37 °C in
a humidified atmosphere of 5 % CO2. Female athymic
BALB/c nu/nu mice (HFK Bioscience, Beijing, China), 3–4
weeks old were maintained at the Animal Core Facility at
West China Hospital, Sichuan University under specific
pathogen-free (SPF) condition. All studies on mice were
conducted in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Tissue specimens
NSCLC tumor and normal adjacent NT tissue specimens
were obtained from 15 patients from Department of
Thoracic Surgery, West China Hospital, Sichuan University
in 2011. This study was performed with the approval of
the Medical Ethical Committee of West China Hospital,
Sichuan University. Ages of the patients ranged from 50 to
81 years (median: 64 years), with a male-to-female ratio
1:2. The tumor specimens encompassed 12 adenocarcin-
oma and 3 squamous cell carcinoma. Tumor specimens
were staged according to TNM classification (2007): stage
I ~ II (10 cases), III (4 cases) and IV (1 case). Tumor sam-
ples were clinically characterized (Table 1).
Quantitative real-time PCR (qPCR) analysis
Total RNA from tissues and cultured cells was isolated
by using Trizol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol. Synthesis of
cDNA with reverse transcriptase was performed by Pri-
meScript RT reagent Kit Perfect Real Time (TaKaRa,
Dalian, China). For SLC34A2 gene expression analysis,
quantitative real-time PCR analysis was done in the iCycler
iQ5 real-time PCR Detection system (Bio-Rad Laboratories,
Hercules, CA, USA) with SYBR Green Reagents (Bio-Rad,
CA). Cycling conditions were used according to the man-
ufacturer’s instructions: 95 °C for 3 min followed by 50 cy-
cles of 95 °C for 10s 58 °C for 20s and 72 °C for 2 min.
Comparative gene expression analysis was performed
using the 2-ΔΔCt method with normalization to the level of
internal control gene GAPDH. The primer sequences used
are as follows: SLC34A2 (F): 5’-GAGAACATCGCCAAA
TGC-3’ (R): 5’-GCAACCACAGAGGACCAG-3’.
Construction and preparation of plasmids
According to the SLC34A2 cDNA coding sequence
(GeneBank, NM_006424), the upstream primer SLCS4A2
(F: 5’- GCGGATCCTAATGGCTCCCTGGCCTGAAT-3’)
and downstream primer SLCS4A2 (R: 5’-GCGAATTCCT
ACAAGGCCGTGCATTCG -3’) were used to clone CDS
sequence of SLCS4A2 from the original cloning vector,
pcmv-sport6-SLCS4A2 (Open Biosystems, USA). The
cloned cDNA sequence was connected to the eukaryotic
expression vector pcDNA3.1 (+) (Invitrogen, Carlsbad,
CA, USA) by DNA Ligation Kit Ver.2.0 (TaKaRa, Dalian,
China) to form a reconstructed plasmid named pcDNA3.1-
SLC34A2. Pure pcDNA3.1 and pcDNA3.1-SLC34A2 plas-
mids were prepared using Tenderfeet Plasmid Giga Kit
(Siegen, Chatsworth, CA, USA) for the following experi-
ments. The construct was confirmed by DNA sequence
analysis to verify its identity and absence of mutation.
Transient transfection
The NSCLC cell lines A549, H1299, H358, H460, 95D
and SK-MES-1 were transfected with either pcDNA3.1-
SLC34A2 recombinant or pcDNA3.1 vector-alone plasmids
with Lipofectamine2000 Reagent (Invitrogen, Carlsbad,
CA, USA) according to manufacturer’s instruction. Cells
transfected with pcDNA3.1-SLC34A2 or pcDNA3.1 were
named as P-S or P respectively. Untransfected cells were
named as Control.
Stable transfection
For stable transfection of SLC34A2 in A549 cells, A549
cells were prepared in 6-well plates. When cell density
reached 60–70 %, they were transfected with the plasmid
pcDNA3.1-SLC34A2 or pcDNA3.1 using Lipofecta-
mine2000 (Invitrogen, Carlsbad, CA, USA). The medium
was replaced after 48 h and G418 (800 μg/ml) (Sigma,
CA, USA) was added to select stable transfectants. After
14 days, G418 sulfate (geneticin)-resistant colonies were
isolated by medium containing G418 and expanded.
The SLC34A2-positive transfected cells were identified
by western blot. Stable transfectants were maintained
in the medium containing G418 (500 μg/ml). A549 cells
with stably expressing pcDNA3.1-SLC34A2 and pcDNA3.1
were named as A549-pcDNA3.1-SLC34A2 (A549-P-S) and
A549-pcDNA3.1 (A549-P) respectively for further analysis.
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Measurement of inorganic phosphate
After transient transfection with pcDNA3.1-SLC34A2, the
phosphorous concentration in supernatant of medium
was measured using a phosphorous measurement kit
(Jiancheng Bioengineering Institute, Nanjing, China) ac-
cording to the manufacturer’s instructions. RIPM-1640 or
DMEM medium was taken as a comparison.
Cell viability assay
To investigate the effects of SLC34A2 on proliferation of
NSCLC cells in vitro, A549, H1299, H460, H358, 95D
and SK-MES-1 cells were transfected with pcDNA3.1-
SLC34A or pcDNA3.1 respectively. Cells untransfected
served as controls. After 48 h treatments, cell medium
was replaced with 20 ml of MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma, St
Louis, MO, USA) in each well, together with 180 ml
RPMI1640, and incubated for another 4 h. The cell via-
bility was evaluated by MTT assay. The percentage of vi-
able cells was calculated in terms of the absorbency of
treated cells relative to that of untreated cells.
Cell apoptosis ratio assay
After transient transfection for 48 h, the cell apoptosis
ratio was determined with Annexin-V and PI staining
Kit (KeyGEN, Nanjing, China) by Fluorescence-activated
cell sorting (FACS) according to the manufacturer’s in-
structions. Untransfected cells served as controls.
In vitro migration and invasion assays
After transient transfection, migration and invasion as-
says were performed using millicell chambers of 8 μm
pore size (Millipore, Billerica, MA) and Boyden Cham-
bers (BD Biosciences, USA) with matrigel coated before
using, respectively. Briefly, for migration, transfected
cells were resuspended in serum-free medium, and
200 μl of the cell suspension (5 × 104 cells) was added to
the upper chamber, the lower compartments were filled
with medium containing 1 % FBS. The chamber was
then cultivated in 5 % CO2 at 37 °C for 24 h. For inva-
sion assays, 2 × 105 cells in 1 % FBS medium were added
to the upper chamber, and the lower compartments were
filled with medium containing 10 % FBS respectively.
After incubating for 24 h, cells that had attached to the
lower surface of the filter were fixed and stained with
0.1 % crystal violet. Cells untransfected served as controls.
The numbers of the migrating and invading cells were cal-
culated by counting the mean number of six random areas
under a light microscope at 200× magnification.
In vivo tumorigenicity assay
All groups of cells were injected subcutaneously into
the right flank of nude mice with the concentration of
7.5 × 106 cells/0.1 ml per mouse. Each group contained
3 mice. Tumor size was measured every 2d by using a
venire calliper. The tumor volume was calculated by the
formula 1/6πab2 (π = 3.14; a = long axis and b = short
axis of the tumor). About sixty days after injection,
Table 1 Patient clinical features and SLC34A2 expression profile
Patient No. Age Gender Histological grade Clinical stage Normalised SLC34A2 amount in tumour tissue
relative to adjacent normal tissue 2-ΔΔCt
Lymph node metastatic or
non-metastatic
1 54 F A IIIA 0.5675 Yes
2 53 F A IA 0.0715 No
3 74 F A IIA 0.0585 Yes
4 71 M A IB 0.1675 No
5 52 F A IB 0.2573 No
6 59 F A IIIB 0.2829 Yes
7 79 F A IB 0.4157 No
8 74 F A IB 0.3364 No
9 61 F A IIIA 0.1702 Yes
10 69 F A IIB 0.4994 No
11 64 F A IIA 3.3600 No
12 67 M A IIA 0.6622 No
13 81 M S IV 0.2813 Yes
14 50 M S IIA 0.1462 No
15 55 M S IIIA 0.5016 Yes
a. M male, F female, A adenocarcinoma, S squamous cell carcinoma. b. Relative quantification was performed by the 2-ΔΔCt method with the adjacent normal lung
tissue sample as a calibrator. Data show the means from three independent analyses. Every independent analysis was carried out after the RNA extraction step.
Total RNA was poly-A tailed, reverse transcripted, and then real-time PCR tested. ΔCT obtained from real-time PCR was subject to paired t-test (ΔCT = CTSLC34A2-CTβ-actin).
The expression levels of SLC34A2 in tumor tissues were significantly lower than adjacent normal tissues (P < 0.05)
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animal were sacrificed and flank tumors were removed and
weighed. Half of each group of tumor samples were fixed
in 4 % paraformaldehyde for histological analysis, and the
others were harvested immediately and freshly frozen.
Lung metastasis model
All groups of cells were injected intravenously via tail
vein with the concentration of 3 × 106 cells/0.2 ml per
mouse. Each group contains 6 mice. Four weeks later,
lungs from the mice of the three groups were injected
intratrachealy with India ink and fixed in AAF solution,
and the number of surface lung metastatic nodules was
counted under a dissecting microscope.
Western blot analysis
Cell lysates from A549, 95D, A549-P-S, A549-P, 95D-P-S,
95D-P cells were prepared by extracting proteins with
RIPA buffer (Pierce) containing protease inhibitor cocktail
set I (Merck KGaA, Germany). The protein concentra-
tions were measured by the BCA protein assay reagent
(Pierce Biotechnology, Rockford, IL, USA). An equal
amount of total proteins was loaded on each lane and
separated by SDS-PAGE and subsequently blotted on a
PVDF membrane (pore size, 0.45 am; Millipore, Billerica,
MA). Membranes were incubated with blocking buffer for
60 min at room temperature and then incubated with a
specific primary antibody against SLC34A2 (Sent Cruz
Biotechnology, Santa Cruz, CA, USA), Cycling D3, PI3
Kinas, phospho-Akt (Ser473), Akt, phospho-mTOR
(Ser2448), mTOR, phospho-MEK1/2 (Ser217/221),
MERK1/2, phospho-p44/p42 MAPK (Erk1/2) (Thr202/
Tyr204), Erk1/2 (Cell Signal pathway Technology,
Beverly, MA, USA) and GAPDH (Sigma, CA, USA) with
Blotto overnight at 4 °C. The membranes were washed
and incubated with a horseradish peroxidase (HRP)-
conjugated secondary antibody. Blots were then exposed
to secondary antibodies and visualized by an enhanced
chemiluminescence (ECL) blotting analysis system (GE
Healthcare Life Sciences, Piscataway, NJ).
Statistical analysis
All results represented the arithmetic mean ± SD stand-
ard error of triplicate determinations of at least three in-
dependent experiments done under the same conditions.
The significant difference of the experimental results
was calculated using one-way ANOVA and an unpaired
Student’s t-test with SPSS13.0 software. P < 0.05 was
considered as statistically significant.
Results
Expression of SLC34A2 in human NSCLC tissues and cell lines
To determine expression levels of SLC34A2 in human
NSCLC, RT-PCR was done in 15 matched NSCLC
tumor/ corresponding adjacent normal tissues and 6
NSCLC cell lines, including A549, H1299, H358, H460,
95D and SK-MES-1. As shown in Table 1, the mRNA
expression levels of SLC34A2 were notably down-
regulated in NSCLC tumor tissues compared with their
normal counterparts. The expression levels of SLC34A2
showed no difference among age, gender, case type,
TNM staging or metastasis in 15 tested lung cancer tis-
sues. In addition, our result also found that the expres-
sions of SLC34A2 in A549, H1299, H358, H460, 95D
and SK-MES-1 cells were reduced by 100.52, 59.02, 1.74,
11.95, 55.73, 42.07 fold, respectively, compared to HBE
(Fig. 1a). These data showed that the expressions of
SLC34A2 were frequently down-regulated in NSCLC tis-
sues as well as in NSCLC cell lines. It indicated that the
down-regulation of SLC34A2 might be involved in the
tumorigenesis of NSCLC.
Expression and Function after transient transfection of
SLC34A2 cDNA
Firstly, the expression levels of SLC34A2 in A549,
H1299, H358, H460, 95D and SK-MES-1 cell lines with
pcDNA3.1-SLC34A2 transient transfection for 48 h were
determined by quantitative real-time PCR. As shown in
Fig. 1b, SLC34A2-transfected cells (P-S) expressed sig-
nificant high mRNA levels of SLC34A2 compared with
untransfected cells (Control) and pcDNA3.1-transfected
cells (P) (P < 0. 01). And the expressions of SLC34A2 in
6 SLC34A2-transfected cells (P-S):A549, H1299, H358,
H460, 95D and SK-MES-1 cells were significantly in-
creased by 1813.43, 313.86, 80.28, 438.96, 824.88, 991.84
fold respectively, compared with matched untransfected
cells (Control). These results indicated the exogenous
SLC34A2 could be efficiently expressed in 6 NSCLC cell
lines after transient transfection.
To verify whether the SLC34A2 was functional available
in SLC34A2-transfected cells, Phosphorous concentration
in the supernatant of medium was measured using a phos-
phorous measurement kit after 48 h transient transfection.
The phosphorous concentration in the supernatant was
reduced in SLC34A2-transfected cells compared with
untransfected cells (Control) and vector-transfected cells
(P) (P < 0. 01) (Fig. 1c). The phosphorous concentration in
the supernatant of SLC34A2-transfected cells (P-S): A549,
H1299, H358, H460, 95D and SK-MES-1 cells were re-
duced by 0.30, 0.24, 0.07, 0.14, 0.23, 0.12 fold, respectively,
compared with matched untransfected cells (Control) and
vector-transfected cells (P). These results further showed
that SLC34A2 could be efficiently expressed and normally
function its transportion of phosphate after transient
transfection in 6 NSCLC cell lines.
Effect of SLC34A2 on proliferation and apoptosis in vitro
To investigate the effects of SLC34A2 on proliferation of
NSCLC cells in vitro, A549, H1299, H460, H358, 95D
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and SK-MES-1 cells were transfected with pcDNA3.1-
SLC34A2 respectively. After 48 h treatment, living cells
were detected by MTT assay. As shown in Fig. 2a, com-
pared with untransfected (Control) and pcDNA3.1-
transfected cells (P), the significant inhibition of cell
proliferation after treated with pcDNA3.1-SLC34A2 was
observed in A549, H1299, H358, 95D and SK-MES-1
cell lines. The growth ratio of A549, H1299, H358, 95D
and SK-MES-1 cell lines was significantly reduced by
42.9 %, 19.6 %, 38.6 %, 26.7 %, 27.1 %, respectively, com-
pared with untransfected cells. However, MTT assay re-
vealed that SLC34A2 had no effect on proliferation of
H460 cells. These results indicated that except for H460,
exogenous expression of SLC34A2 significantly inhibited
the viability of A549, H1299, H358, 95D and SK-MES-1
cells in vitro.
To determine the effect of SLC34A2 on apoptosis of
NSCLC in vitro, we examined Annexin V positivity by
fluorescence-activated cell sorting (FACS). As shown in
Fig. 1 SLC34A2 expression was down-regulated in NSCLC cell lines
and SLC34A2 was re-expressed in SLC34A2-transfected cells. a mRNA
levels of SLC34A2 in six NSCLC cell lines were determined by RT-PCR.
HBE cells served as control. b mRNA levels of SLC34A2 in six NSCLC cell
lines were detected by RT-PCR after transfected with pcDNA3.1-SLC34A2
(P-S) or pcDNA3.1 (P) for 48 h, untransfected cells was named as Control.
c The concentration of phosphorous in the supernatant of medium was
measured by using a phosphorous measurement kit after 48 h
transient transfection
Fig. 2 SLC34A2 inhibited cell growth but had no effect on apoptosis.
a Cell viability assay. A549, H1299, H460, H358, 95D and SK-MES-1 cells
were transfected with pcDNA3.1-SLC34A2 or pcDNA3.1 respectively.
After 48 h treatments, living cells were detected by MTT assay.
b After transient transfection for 48 h, cell apoptosis ratio was
determined with Annexin-V and PI staining Kit by Fluorescence-activated
cell sorting (FACS)
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Fig. 2b, the ratio of apoptosis in A549, H1299, H358,
H460, 95D and SK-MES-1 cell lines transfected with
SLC34A2 was just increased by 6.40 %, 8.10 %, 2.70 %,
1.87 %, 5.67 % and 1.80 % respectively, compared with
untransfected cells. As a result, although increasing ex-
pression of SLC34A2 significantly inhibited the viability
of A549, H1299, H358, 95D and SK-MES-1 cells in vitro,
the effects of SLC34A2 on apoptosis of these NSCLC cell
lines were not obvious.
Effect of SLC34A2 on migration and invasion in vitro
To explore the role of SLC34A2 on migration and inva-
sion of NSCLC cell lines, A549, H1299, H460, 95D and
SK-MES-1 were transiently transfected with pcDNA3.1-
SLC34A2 or blank vector in vitro. Then millicell cham-
ber assay and matrigel invasion assay were performed to
determine the invasiveness and migration capability. As
shown in Fig. 3a, SLC34A2-transfected cells (P-S) had
significantly less motile compared with untransfected
(Control) and blank vector-transfected cells (P). The ratio
of cell migration in A549, H1299, 95D and SK-MES-1
cells transfected with SLC34A2 was decreased by 43.16 %,
43.81 %, 30.33 %, and 28.68 % respectively, compared with
the blank control group (Fig. 3b). In addition, as shown in
Fig. 3c, the ability of invasiveness in SLC34A2-transfected
cells was considerably lower than that in negative control
group. The invasion capability of SLC34A2 -transfected
cells was suppressed by 61.59 %, 63.01 %, 47.15 % and
53.75 % respectively (Fig. 3d). However, no significant
effect of SLC34A2 on migratory and invasive ability was
found in H460 cells. These data showed that except for
H460, SLC34A2 played an important role on reduction
of migration and invasion potential in these NSCLC
cells in vitro.
Expression and function after stable transfection of
SLC34A2 cDNA
In order to investigate the effects of SLC34A2 on
tumorigenesis and metastatic potential in vivo, A549
stable transfectants were generated by transfection with
pcDNA3.1-SLC34A2 or pcDNA3.1, and selected by
G418 method. Then, western blot was done to deter-
mine the expression level of SLC34A2 in stable cells.
A549-P-S cells expressed significant high protein levels
Fig. 3 SLC34A2 inhibited migratory and invasive potential after transient transfection for 48 h. a Millicell chamber assay showed reduced cell
migratory ability in SLC34A2-transfected A549, H1299, 95D and SK-MES-1 cells (P-S) compared with untransfected (Control) and vector-transfected
cells (P). b Cell migration ratio of these five NSCLC cell lines was assessed by Matrigel invasion assay. c Matrigel invasion assay showed depressed
cell invasive ability in SLC34A2-transfected A549, H1299, 95D and SK-MES-1 cells compared with untransfected and vector-transfected cells. d Cell
invasion ratio of these five NSCLC cell lines was assessed by Millicell chamber assay
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of SLC34A2, whereas little protein was observed in
A549-P cells. The expression level of SLC34A2 in A549-
P-S cells was higher than A549 cells by 5.6-fold (Fig. 4a).
To verify whether the stably transfected SLC34A2 was
functional, phosphorous concentration in the super-
natant of medium was measured using a phosphorous
measurement kit after stable transfection. As shown in
Fig. 4b, the phosphorous level in the supernatant from
the A549-P-S cells were markedly reduced compared
with A549-P and A549 cells. The result confirmed the
A549 cell line with stable transfection of SLC34A2 was
constructed successfully.
Effect on SLC34A2 on tumor growth and metastasis in vivo
To examine the effect of SLC34A2 on tumor growth of
NSCLC in vivo, a subcutaneous xenotransplanted tumor
model was established with A549-P-S, A549-P or A549
cells. As shown in Fig. 4c, compared with A549 cells,
A549-P-S cells exhibited a significantly slower growth rate
in vivo. In addition, the average wet weight of tumors from
nude mice injected with A549-P-S cells was less than that
from nude mice injected with A549 cells (Fig. 4d). These
results suggested that SLC34A2 might play an important
role in the inhibition of tumor growth in vivo of NSCLC.
To evaluate the effect of SLC34A2 on tumor metastasis
of NSCLC in vivo, a lung metastasis model in nude mice
was established with A549-P-S, A549-P and A549 cells re-
spectively. As shown in Fig. 4e, 28 days later, lungs from
the mice of the three groups were injected intratrachealy
with India ink and fixed in AAF solution, and the numbers
of surface lung metastatic nodules were counted under a
dissection microscope. We found that all of the nude mice
injected with A549 or A549-P cells had shown more and
larger lung nodules than nude mice injected with A549-P-S
Fig. 4 SLC34A2 suppressed tumor growth and lung metastasis of NSCLC in vivo. a The expressions of SLC34A2 in A549-P-S, A549-P and A549 cells
were confirmed by Western blot. b The concentrations of phosphorous in the supernatant of medium were measured by using a phosphorous
measurement kit in A549-P-S, A549-P and A549 cells. c Tumor growth curve (each group contained 8 mice). d Tumor wet weight. Mice were
killed for measurement of tumor weight at 60 days after inoculation. e Lungs from mice injected with A549-P-S, A549-P and A549 cells were
injected intratracheally with India ink and fixed in AAF solution. f The numbers of lung nodules were counted under a dissecting microscope
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cells (Fig. 4f). These results further suggested that SLC34A2
might play an important role in the suppression of invasion
and metastasis of NSCLC.
Effect of SLC34A2 on expression level of related signaling
proteins
Recent studies suggested that anomalous expression of
SLC34A2 might promote tumorigenesis of lung cancer
by the activation of PI3K-Akt and Ras/Raf/MEK/ Erk
pathways. To understand the mechanism of SLC34A2
involved in tumorigenesis and progression of NSCLC,
western blot was performed to detect the expression
levels of related signalling protein, including PI3 Kinase,
phospho-AKT, AKT phospho-mTOR, mTOR, phospho-
MEK1/2, MEK1/2, phospho- Erk1/2, Erk1/2 and Cyclin
D3 in A549 and 95D cells, which were transiently trans-
fected with pcDNA3.1-SLC34A (P-S) or pcDNA3.1 (P)
for 48 h respectively. The results showed that there were
not significant changes in the expression of AKT,
mTOR, MER and Erk1/2 in P-S group (A549 and 95D),
comparing with their control counterparts respectively.
As shown in Fig. 5, a marked reduction in PI3 Kinase,
phospho-Akt, phospho-mTOR, phospho-MEK1/2, phospho-
Erk1/2 and Cyclin D3 was observed in P-S cells (A549)
comparing with those in control group (A549). In
addition, comparing with those in control group (95D), a
dramatic reduction of phospho-MEK1/2 and phospho-
Erk1/2 was detected in P-S cells (95D). However, the ex-
pression levels of phospho-Akt and Cyclin D3 were
slightly decreased without statistical significance. More-
over, the levels of PI3 Kinase and phospho-mTOR had no
detectable changes in P-S cells (95D).
Discussion and conclusions
In 2008, Eugene P. Kopantzev reported that the average
expression level of SLC34A2 was reduced by 9-fold com-
pared with surrounding normal lung tissues [9]. In this
report, we have also found that SLC34A2 was down-
regulated in 12 adenocarcinoma and 3 squamous carcin-
oma, and the lowest expression level of SLC34A2 was
decreased by 16-fold. Besides, for the first time, our results
showed that SLC34A2 was significantly down-regulated in
lung adenocarcinoma cell lines (A549, H1299), bronchoal-
veolar carcinoma cell line (H358), lung large cell carcin-
oma cell lines (H460, 95D) and lung squamous carcinoma
(SK-MES-1). Our results suggested SLC34A2 with signifi-
cant down-regulation in NSCLC tissues and cell lines
might play an important role in tumorigenesis of NSCLC.
In our study, we further found that SLC34A2 could
perform a dramatic inhibitory effect on cell growth, mo-
tility and invasiveness in A549, H1299, 95D and SK-
MES-1 cells. H358 cells are non-invasive, thus SLC34A2
just caused growth inhibition of H358 cells. However,
SLC34A2 had no inhibition effects on cell growth, motil-
ity and invasiveness in H460 cells. Besides, SLC34A2 did
not induce any apoptosis in these six NSCLC cell lines.
Moreover, we found that SLC34A2 notably suppressed
tumorigenicity and lung metastasis ability in vivo. For
the first time, our results indicated the suppressive ef-
fects of SLC34A2 on cell growth, motility and invasive-
ness in human NSCLC cell lines. It suggested that
SLC34A2 might be a new suppressor gene in NSCLC.
However, SLC34A2 might play different roles in different
NSCLC cell lines.
Accumulated studies have pointed out the similarity
between embryonic development and tumorigenesis
[11, 12]. Genes which affect tumorigenesis usually influ-
ence embryonic development, while genes which regulate
normal differentiation usually participate in tumorigenesis
[13, 19]. However, the expression of these genes in
tumorigenesis and progression were reported to be
opposite to that in embryonic development. Genes which
increased their expression levels during embryonic
development usually had increased expression levels in
tumorigenesis [20], such as Cav1. It is widely known
that Cav1 is implicated in embryonic development [21].
Fig. 5 Relative signal pathways were determined by Western blot.
There were not significant changes in the expressions of Akt, mTOR,
MER1/2 and Erk1/2 in P-S (A549 and 95D) comparing with their
control counterparts respectively. SLC34A2-tranfected A549 cells
exhibited reduced expression levels of PI3K, p-Akt, p-mTOR, p-MEK1/2,
p-Erk1/2 and CyclinD3. No significant changes in expression levels of
PI3K, p-Akt, p-mTOR and CyclinD3 were found between SLC34A2- and
vector- transfected 95D and 95D cells, whereas expressions of p-MEK1/2
and p-Erk1/2 in SLC34A2-transfected 95D cells were reduced (Cells
transfected with pcDNA3.1-SLC34A2 or pcDNA3.1 were named as P-S or
P respectively. Untransfected cells were named as Control.)
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The low expression of Cav1 facilitated tumorigenesis
and progression of lung cancer [22]. Another example
was the epidermal growth factor-Cripto-1. During early
embryogenesis, Cripto-1 proteins performed an import-
ant role. Moreover, expression of Cripto-1 was in-
creased in several human cancers and its overexpression
is associated with the development of mammary tumors
in mice [19]. Eugene P. Kopantzev reported the low ex-
pression level of SLC34A2 in human NSCLC tissues.
Meanwhile, our results showed that SLC34A2 was
down-regulated both in human NSCLC tissues and cell
lines. Besides, Eugene P. Kopantzev also reported that
SLC34A2 was up-regulated during embryonic develop-
ment. The opposite expression level of SLC34A2 in
NSCLC and embryonic development was similar to
Cav1 and Cripto-1. It indicated that SLC34A2 might be
implicated in tumorigenesis and development of
NSCLC.
To explore the pathogenesis of cancer, Reya firstly de-
scribed the principles of cancer stem cell biology. It was
well known that cancer stem cells might be the origin of
tumor. It was derived from malignant transformation of
normal stem cells after undergoing exogenous or endogen-
ous factors [23]. Some studies showed that ATII cells were
the stem cells of both ATI and ATII cells [24]. ATII cells
might serve as original cells of pathogenesis of lung cancer.
Some studies showed that uncontrolled proliferation of
ATII cells might result in lung adenocarcinoma [25, 26].
Besides, ultrastructural and immunohistochemical studies
performed in human lung cancer tissues found the pres-
ence of ATII cells [15, 16, 27–30]. TenHave-Opbroek also
indicated that human ATII cells, as a pluripotential stem
cell, were abnormally differentiated into ATII tumor stem
cells after undergoing exogenous or endogenous factors.
These tumor stem cells might invade the surrounding con-
nective tissue and attempt to form adenocarcinoma [30]. In
addition, ATII cells were also detectable in human squa-
mous cell carcinomas and large cell carcinomas, although
less frequently [16, 17, 30]. All these studies indicated that
ATII cells which acted as normal stem cells, possibly trans-
formed into cancer stem cells and ultimately induced
tumorigenesis of NSCLC, especially adenocarcinoma. How-
ever, the mechanism of malignant transformation in ATII
cells is unclear untill now.
For the first time, our results found that SLC34A2 was
significantly down-regulated both in NSCLC tissues and
cell lines. Our further results showed that SLC34A2 di-
minished cell growth, motility and invasiveness of some
NSCLC cell lines in vitro. SLC34A2 also significantly at-
tenuated tumorigenicity and lung metastasis ability in
vivo. These results indicated that SLC34A2 might play
an important role in the malignant transformation of
ATII cells. Moreover, several studies proved a closer
relationship between ATII cells and tumorigenesis of
adenocarcinoma [15, 16, 27–30]. Our results also showed
that SLC34A2 was generally down-regulated in adenocar-
cinoma tissues and cell lines, while SLC34A2 significantly
diminished cell growth, motility and invasiveness in A549
and H1299 cells. It suggested that the dysregulation of
SLC34A2might be more closely associated with tumorigen-
esis and progression of adenocarcinoma.
The role of SLC34A2 is to transport phosphate and
maintain phosphate balances [6]. Phosphate played a
critical role during organ development (eg. brain, lung)
and tumorigenesis through regulating cell differentiation
and gene expression. Recently, Seung-Hee Chang
showed that high concentration of phosphate treatment
on non-tumorigenic human bronchial epithelial cells
(NHBE) increased expression of sodium/phosphate co-
transporter IIa (NaPi-IIa) protein and promoted cell
growth through activation of Akt-mediated Raf-MEK-Erk
signal pathway [31]. Besides, Hua Jin clearly demonstrated
that high or low dietary phosphate could influence normal
expression of SLC34A2 and affect cell cycle and angiogen-
esis via activation of PI3K-Akt-mTOR signal pathway
during lung development [32, 33]. Furthermore, high or
low dietary phosphate increased NaPi-IIb protein levels in
lungs of K-rasLA1 mice and stimulated lung tumorigenesis
by activation of PI3K-Akt-mTOR signal pathway [34, 35].
All this studies indicated that aberrant concentration of
endocellular phosphate might be relative with tumorigen-
esis of lung cancer. SLC34A2 encodes the exclusive
phosphate transporter protein in ATII cells, and it was vital
for maintaining the balance of phosphate in ATII cells.
Therefore, SLC34A2 may be relative with tumorigenesis of
lung cancer.
PI3K-Akt signal pathway which was frequently hyper-
activated in lung cancer, contributed to oncogenesis and
tumor growth [36]. Aberrant activation of this signal
pathway promoted cell proliferation by means of modu-
lating the function of numerous substrates, such as
mammalian target of rapamycin (mTOR). Akt increased
the phosphorylation of mTOR, which promoted expres-
sion of CyclinD and regulated the functions of transla-
tional regulators [37]. Several pieces of evidence attest to
the promotion of hyperactivation of PI3K-Akt signal
pathway in tumor cell migration and invasion [38, 39].
In addition, PI3K signaling pathway had been shown to
be important to maintain pluripotency in mouse ESC.
Moreover, mutations in the PI3K/AKT pathway inhibitor
had been found in lung carcinomas. Activation of this
pathway promoted cancer cells survival and proliferation
[12]. Ras-Raf-MEK-Erk signal pathway which was also
hyperactivated in lung cancer played a vital role in regu-
lating tumor cell growth, survival and differentiation,
impacting directly on the formation and progression of
tumors [40]. Besides, PI3K-Akt signal pathway had been
reported to cross-talk with Ras-Raf-MEK-Erk signal
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pathway [31]. Our results showed that expression levels
of PI3 Kinase, phospho-Akt, phospho-mTOR, phospho-
MEK1/2, phospho-Erk1/2 and Cyclin D3 were remark-
ably reduced after re-expression of SLC34A2 in A549
cells. The results indicated that the effect of SLC34A2
on proliferation and metastasis might depend on sup-
pressing the activation of PI3K-Akt-mTOR and Ras-Raf-
MEK-Erk signal pathways in A549 cells. However, no
significant changes in expression level of PI3 Kinase,
phospho-Akt, phospho-mTOR and Cyclin D3 were
detected, while the levels of phospho-MEK1/2 and
phospho-Erk1/2 was dramatically reduced after re-
expression of SLC34A2 in 95D cells. These results sug-
gested that SLC34A2 could repress the activation of
Ras-Raf-MEK-Erk signal pathway, but had no effects on
PI3K-Akt-mTOR signal pathway and CyclinD3 in 95D
cells. Taken together, these facts indicated that the low
expression of SLC34A2 in type II alveolar epithelium cells
might activate PI3K-Akt-mTOR or Ras-Raf-MEK-Erk
signal pathways, and further promoted tumorigenesis of
NSCLC.
In this study, for the first time, we demonstrated the
general low expression of SLC34A2 in human NSCLC
tissues and cell lines. Our results supported the suppres-
sive effects of SLC34A2 on cell growth, motility and in-
vasiveness in NSCLC in vitro and in vivo. We concluded
that SLC34A2 could act as a new tumor suppressor gene
in NSCLC. Furthermore, our data suggested that low ex-
pression of SLC34A2 might result in tumorigenesis of
NSCLC, and the relative mechanism might be related to
the changes of PI3K-Akt-mTOR and Ras-Raf-MEK-Erk
signal pathways. Our results will be important for under-
standing the early pathogenesis of human NSCLC,
especially adenocarcinoma. Therefore, SLC34A2 might
provide new insights into pathogenesis of NSCLC and
suggest new therapy strategy for NSCLC.
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